Skip to main content

Yesterday, Dec. 17, 2015, 102 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $600.00 to $296,713,529.26.

Highlighted Stocks Traded by Insiders:

ConocoPhillips (COP) - FREE Research Report

Murti Arjun N, who is Director at ConocoPhillips, bought 5,000 shares at $49.90 on Dec. 17, 2015. Following this transaction, the Director owned 5,000 shares meaning that the stake was boosted by 100% with the 5,000-share transaction.

The shares most recently traded at $47.02, down $2.88, or 6.13% since the insider transaction. Historical insider transactions for ConocoPhillips go as follows:

  • 4-Week # shares bought: 7,000
  • 4-Week # shares sold: 1,660
  • 12-Week # shares bought: 7,000
  • 12-Week # shares sold: 1,660
  • 24-Week # shares bought: 7,000
  • 24-Week # shares sold: 1,660

The average volume for ConocoPhillips has been 8.5 million shares per day over the past 30 days. ConocoPhillips has a market cap of $60.9 billion and is part of the basic materials sector and energy industry. Shares are down 31.54% year-to-date as of the close of trading on Thursday.

ConocoPhillips explores for, produces, transports, and markets crude oil, bitumen, natural gas, liquefied natural gas, and natural gas liquids worldwide. The stock currently has a dividend yield of 6%. Currently, there are 7 analysts who rate ConocoPhillips a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on COP - FREE

TheStreet Quant Ratings

rates ConocoPhillips as a

TheStreet Recommends

hold

. Among the primary strengths of the company is its solid financial position based on a variety of debt and liquidity measures that we have evaluated. At the same time, however, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full

ConocoPhillips Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

BMC Stock Holdings (STCK) - FREE Research Report

Bullock David W, who is Director at BMC Stock Holdings, bought 4,000 shares at $15.19 on Dec. 17, 2015. Following this transaction, the Director owned 18,107 shares meaning that the stake was boosted by 28.35% with the 4,000-share transaction.

The shares most recently traded at $15.81, up $0.62, or 3.95% since the insider transaction. Historical insider transactions for BMC Stock Holdings go as follows:

  • 4-Week # shares sold: 20,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 20,000
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 20,000

The average volume for BMC Stock Holdings has been 62,700 shares per day over the past 30 days. BMC Stock Holdings has a market cap of $1.0 billion and is part of the industrial goods sector and materials & construction industry. Shares are up 1.11% year-to-date as of the close of trading on Thursday.

Stock Building Supply Holdings, Inc., together with its subsidiaries, distributes lumber and building materials in the United States. The company has a P/E ratio of 29.8. Currently, there are no analysts who rate BMC Stock Holdings a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on STCK - FREE

TheStreet Quant Ratings

rates BMC Stock Holdings as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and poor profit margins. Get the full

BMC Stock Holdings Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Agios Pharmaceuticals (AGIO) - FREE Research Report

Higgons John Duncan, who is Chief Operating Officer at Agios Pharmaceuticals, sold 20,000 shares at $50.09 on Dec. 17, 2015. Following this transaction, the Chief Operating Officer owned 61,835 shares meaning that the stake was reduced by 24.44% with the 20,000-share transaction.

The shares most recently traded at $55.89, up $5.80, or 10.38% since the insider transaction. Historical insider transactions for Agios Pharmaceuticals go as follows:

  • 4-Week # shares bought: 1,806
  • 4-Week # shares sold: 4,703
  • 12-Week # shares bought: 1,806
  • 12-Week # shares sold: 9,555
  • 24-Week # shares bought: 1,806
  • 24-Week # shares sold: 24,111

The average volume for Agios Pharmaceuticals has been 683,400 shares per day over the past 30 days. Agios Pharmaceuticals has a market cap of $2.1 billion and is part of the health care sector and drugs industry. Shares are down 50.4% year-to-date as of the close of trading on Thursday.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism in the United States. Currently, there is 1 analyst who rates Agios Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AGIO - FREE

TheStreet Quant Ratings

rates Agios Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Agios Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.